Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011;6(5):e20266.
doi: 10.1371/journal.pone.0020266. Epub 2011 May 23.

Autoantibodies against a 43 KDa muscle protein in inclusion body myositis

Mohammad Salajegheh  1 , Theresa Lam, Steven A Greenberg
Affiliations

Autoantibodies against a 43 KDa muscle protein in inclusion body myositis

Mohammad Salajegheh et al. PLoS One. 2011.

Abstract

Background: Inclusion body myositis (IBM) is a poorly understood and refractory autoimmune muscle disease. Though widely believed to have no significant humoral autoimmunity, we sought to identify novel autoantibodies with high specificity for this disease.

Methodology/principal findings: Plasma autoantibodies from 65 people, including 25 with IBM, were analyzed by immunoblots against normal human muscle. Thirteen of 25 (52%) IBM patient samples recognized an approximately 43 kDa muscle protein. No other disease (N = 25) or healthy volunteer (N = 15) samples recognized this protein.

Conclusions: Circulating antibodies against a 43-kDa muscle autoantigen may lead to the discovery of a novel biomarker for IBM. Its high specificity for IBM among patients with autoimmune myopathies furthermore suggests a relationship to disease pathogenesis.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Circulating autoantibodies against a 43 kDa muscle autoantigen in inclusion body myositis (IBM).
Images from all immunoblots are shown. Reactivity is present in 13 of 25 different inclusion body myositis (IBM) plasma samples, but in none of 10 dermatomyositis (DM), 10 polymyositis (PM), 5 myasthenia gravis (MG) or 15 normal volunteer (NL) plasma samples.
See this image and copyright information in PMC

References

    1. Mammen AL. Dermatomyositis and polymyositis: Clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci. 2010;1184:134–153. - PubMed
    1. Dalakas MC, Illa I, Gallardo E, Juarez C. Inclusion body myositis and paraproteinemia: incidence and immunopathologic correlations. Ann Neurol. 1997;41:100–104. - PubMed
    1. Hengstman GJ, Brouwer R, Egberts WT, Seelig HP, Jongen PJ, et al. Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies. J Neurol. 2002;249:69–75. - PubMed
    1. Engel AG, Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol. 1984;16:209–215. - PubMed
    1. Greenberg SA. DNA microarray gene expression analysis technology and its application to neurological disorders. Neurology. 2001;57:755–761. - PubMed

Publication types